CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $3.61B, above the global median of $1.2B
- FinancialsAltman Z-Score 1.2: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.58%
Annual Rate
USD 0.08Paid quarterly
Payout Ratio
10.3%Sustainable
Paying Dividends
6 yr
Last Ex-Dividend
Aug 14, 2026
Last Payment
Sep 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.61BUSDvs all stocks (USD)
Trailing P/E
17.60xRevenue (TTM)
6.13BUSDvs all stocks (USD)
Profit Margin
3.41%Beta
1.52xvs all stocks
52-Week Change
32.66%vs all stocks
Forward Annual Dividend Yield
0.58%vs all stocks
Market Capitalization
3.61BUSDvs all stocks (USD)
Enterprise Value
11.03BUSDvs all stocks (USD)
Trailing P/E
17.60xForward P/E
3.80xPEG Ratio
-0.6572xPrice to Sales (TTM)
0.5885xPrice to Book (MRQ)
3.58xEnterprise to Revenue
1.80xEnterprise to EBITDA
7.05xGross Margin
54.36%Profit Margin
3.41%Operating Margin
20.73%Return on Assets (TTM)
5.67%Return on Equity (TTM)
24.04%Revenue (TTM)
6.13BUSDvs all stocks (USD)
Revenue per Share (TTM)
23.49USDUpdated Sep 28, 2026Quarterly Revenue Growth
-2.30%Gross Profit (TTM)
3.27BUSDvs all stocks (USD)
EBITDA (TTM)
1.68BUSDvs all stocks (USD)
Net Income (TTM)
209.00MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.50%Operating Cash Flow (TTM)
737.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
490.75MUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.0800USDUpdated Sep 28, 2026Forward Annual Dividend Yield
0.58%vs all stocks
Trailing Annual Dividend Rate
0.0800USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.58%vs all stocks
Payout Ratio
10.26%Revenue
6.22BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.90BUSDFY2025 · Dec 31, 2025Gross Profit
3.31BUSDFY2025 · Dec 31, 2025Operating Income
1.23BUSDvs all stocks (USD)
Pre-tax Income
425.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
238.00MUSDFY2025 · Dec 31, 2025Net Income
187.00MUSDFY2025 · Dec 31, 2025EBIT
929.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.71BUSDFY2025 · Dec 31, 2025Research & Development
366.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.72BUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
504.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.7200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.7200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
259.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
259.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
187.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
687.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
686.00MUSDDerived from operating cash flow minus capital expenditure. This filing charges 361M of depreciation against 1M of capital expenditure, and its own free-cash-flow line reads 384M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
574.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
187.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
361.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
63.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
77.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
43.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
79.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-217.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
94.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
1.00MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-154.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
-75.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-74.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
1.05BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.51BUSDFY2025 · Dec 31, 2025Common Dividends Paid
-88.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-15.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-561.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
262.61MSharesUpdated Sep 28, 2026Float Shares
242.99MSharesUpdated Sep 28, 2026Shares Short
17.53MSharesUpdated Sep 28, 2026Short Ratio
5.45daysvs all stocks
Short % of Shares Outstanding
7.59%vs all stocks
% Held by Insiders
0.46%vs all stocks
% Held by Institutions
84.81%vs all stocks
Total Cash (MRQ)
1.13BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.31USDUpdated Sep 28, 2026Total Debt (MRQ)
8.55BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
8.50xCurrent Ratio (MRQ)
1.95xBook Value per Share (MRQ)
3.83USDUpdated Sep 28, 2026Total Assets
12.87BUSDvs all stocks (USD)
Total Current Assets
4.35BUSDFY2025 · Dec 31, 2025Total Liabilities
12.12BUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.52BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.72BUSDFY2025 · Dec 31, 2025Total Current Liabilities
2.39BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
574.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.33BUSDFY2025 · Dec 31, 2025Inventory
1.41BUSDFY2025 · Dec 31, 2025Accounts Payable
952.00MUSDFY2025 · Dec 31, 2025Short-term Debt
16.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.00MUSDFY2025 · Dec 31, 2025Long-term Debt
8.63BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.01BUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00MUSDFY2025 · Dec 31, 2025Retained Earnings
1.11BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
752.00MUSDvs all stocks (USD)
52-Week Low
5.69USDUpdated Sep 28, 202652-Week High
13.79USDUpdated Sep 28, 202652-Week Change
32.66%vs all stocks
Beta
1.52xvs all stocks
50-Day MA
13.66USDUpdated Sep 28, 2026200-Day MA
10.72USDUpdated Sep 28, 2026Avg 10-Day Volume
2.22MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.90MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.7800USDUpdated Sep 28, 2026Other Income / Expense
-297.00MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Debt Financing Activity
More cash moved through borrowing and repaying than through the business itself, and most of its debt is long-term.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: 0.03
Financial Health
Altman Z-Score 1.2: grey zoneSignificant
Altman Z-Score: 1.20
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $3.61B, above the global median of $1.2BNotable
Market cap (USD): 3,605,627,515Global Median: 1,201,862,193
Revenue is $6.13B, above the global median of $558.46MNotable
Revenue (USD): 6,127,000,064Global Median: 558,459,881.051
Levered free cash flow is $490.75M, above the global median of $18.92MNotable
Levered free cash flow (USD): 490,750,016Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Highbroad Advanced Material Co. Ltd.
1 interpretationWithin or Near the Altman Distress Zone